SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AdventRX Pharmaceuticals, Inc. (Note: Request metadata listed "Savara Inc", but the filing identifies AdventRX Pharmaceuticals, Inc.)
Filing Date: April 4, 2005
Reporting Period: The filing addresses the 2004 Fourth Quarter and Full Year financial results.
Event: Issuance of a corrected press release regarding the aforementioned financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves solely to announce the correction of a previously issued press release; the actual financial figures are contained in the attached exhibit (Exhibit 99.1) which is not included in the provided text.
Material Changes
The material change reported is the correction of financial data previously announced for the 2004 Fourth Quarter and Full Year. The filing does not detail the specific numerical differences between the original and corrected reports.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a procedural filing to ensure the accuracy of public disclosures regarding past performance.
Investor Verification Checklist
- Verify the specific corrected financial figures in the attached Exhibit 99.1 (Press Release dated April 4, 2005).
- Compare the corrected 2004 Fourth Quarter and Full Year results against the original press release to identify the nature and magnitude of the error.
- Confirm if the correction impacts any prior analyst estimates or credit agreements.